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Abstract
Background Older adults with cancer experience negative long-term functional effects of both cancer and treatments. Exer-
cise may minimize their age-related and cancer-related functional decline.
Methods We conducted a multicentre open-label 12 month randomized clinical trial with two parallel arms including partic-
ipants aged ≥70 years with lymphoma or carcinoma requiring curative treatment. The study started at the beginning of any
phase of cancer treatment (surgery, chemotherapy, or radiotherapy). The usual care group (UCG) received the current national
recommendations in physical activity (a guideline without specific counselling). The intervention group (IG) received 1 year
phoned physical activity advice individually adapted to physical assessment (twice a month during the first 6 months and then
monthly). The primary outcome was the proportion of subjects with a 1 year decreased short physical performance battery
(SPPB) score of 1 point or more. Physical, cognitive, and clinical secondary outcomes were also investigated.
Results We allocated 301 participants (age 76.7 ± 5.0, female 60.6%) to each group. At baseline, the median SPPB was 10/12
in both groups. Breast was the most frequent tumour site (35.7%). After 1 year, 14.0% of participants in the UCG and 18.7% in
the IG had a decrease in SPPB score of 1 point or more (P = 0.772). At 2 years, there was no difference in SPPB, gait speed,
International Physical Activity Questionnaire score, and verbal fluency. Subgroup analyses after 2 years showed a decline in
SPPB for 29.8% of UCG and 5.0% of IG breast cancer participants (P = 0.006), in 21.7% of UCG and 6.2% of IG female partic-
ipants (P = 0.019), and in 24.5% of UCG and 11.1% of IG normal nutritional status participants (P = 0.009). Falls, hospitalization,
institutionalization, and death rates were similar in both groups.
Conclusions Personalized phoned physical activity advice had not reduced functional decline at 1 year but provided prelim-
inary evidence that may prevent physical performance decline at 2 years in older adults with breast cancer.
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Introduction
Cancer is frequent in older adults. By 2040, nearly three out
of four cancer survivors will be 65 years and older.1 Cancer
survivors are known to experience long-term negative effects
of treatment such as fatigue, pain, cognitive disturbance, de-
pression, anxiety, and reduced health-related quality of
life.2,3 Compared with other older adults, they are at greater
risk of other cancers, cardiovascular disease, osteoporosis, di-
abetes, and accelerated functional decline.4 However, most
survivorship studies have focused on childhood cancer or
cancer in young adults but not in older adults.5
The long-term outcome of successfully treated cancer pa-
tients is relatively unknown except for their vital prognosis.6,7
Furthermore, the functional consequences of cancer may be
greater in elderly than in younger adults.6 It is important to
encourage older cancer survivors to adopt a healthy lifestyle
with physical activity together with a health-care plan that in-
cludes a dynamic conversation focused on education and mo-
tivation between patients and their health-care providers.8
Frailty is associated with a high risk of dependency, falls,
cognitive decline, infections, hospitalization, disability, institu-
tionalization, and death.9–11 The most frequently used criteria
to define frailty are the set proposed by Fried and colleagues
that includes five conditions: exhaustion, slowness, weight
loss, low physical activity, and muscle weakness.12 A growing
body of evidence indicates that frailty is a dynamic syndrome
characterized by frequent transitional stages that can be
modified.11,13 Thus, an intervention that could prevent frailty
or reduce its severity would be of great interest for older pa-
tients with cancer.
The National Cancer Institute and the National Academy of
Medicine of the USA have highlighted the need to address
functional outcomes during and after oncology interventions
more robustly.14 Physical performance measures can predict
onset of disability, and gait speed alone15 or in combination
with other measures like the short physical performance bat-
tery (SPPB) is a strong predictor of adverse outcomes like mor-
tality, hospitalization, or disability.16Nevertheless, few studies
have established standardized and objective measures of
physical function that are highly associated with an increased
risk of disability, nursing home admission, and mortality.16
Older cancer survivors report low physical activity levels,
and few meet recommended health promotion guidelines.17
Successfully engaging older adults in a regular and consistent
physical activity programme can be challenging. The latter
may face obstacles that make participation less likely: inability
to travel to centres with supervised programmes, health con-
cerns related to unsupervised physical activity, and lack of
knowledge regarding appropriate exercise activities.18 Al-
though home-based programmes are associated with re-
duced effects on change in health-related quality of life and
physical function outcomes relative to centre-based initia-
tives, home-based programmes have the potential to reach
a broader segment of the population at considerably lower
cost.18 Furthermore, reference centres for cancer treatment
may be far from older patients’ homes, making participation
in supervised programmes even more difficult. Thus, physical
activity programmes that offer advice and support at regular
intervals by phone may provide a necessary bridge for suc-
cessful home-based exercise in older adults with cancer.
Telephone-based physical activity interventions have been
proposed to allow for greater outreach to patients and mini-
mize the high number of participants who refuse to attend
supervised exercise sessions after cancer diagnosis due to
the lack of interest in exercise, living too far away to travel,
or because they are too busy.19
The aim of this study was to compare individualized
adapted phone advice for 1 year to usual care in patients
aged 70 and older with good-prognosis cancer and undergo-
ing curative treatment. We tested the hypothesis that provid-
ing phone advice on exercising including strength, balance,
proprioception, flexibility, and aerobic training for 1 year
could prevent physical performance loss at 1 year as com-
pared with a control arm. The prevention of physical perfor-
mance loss at 2 years and better evolution of gait speed,
physical activity level, and cognition (verbal fluency) at 1
and 2 years after the start of cancer treatment were analysed
as secondary outcomes.
Methods
Study design
CAPADOGE (Conseils en Activité physique pour la Prévention
de la perte d’Autonomie Des patients d’Onco-GEriatrie) was a
multicentre open-label 12 month randomized clinical trial
with two parallel arms conducted in 12 recruiting centres in
France. The intervention took place between October 2011
and May 2016. The University Hospital of Bordeaux coordi-
nated the study and performed data management, analysis,
and quality control. The subjects received the intervention
from the start of any phase of their cancer treatment that
was surgery, chemotherapy, or radiotherapy.
Patient population
Details of the methods were published previously.20 Briefly,
the population consisted of men and women aged ≥70 years
with histological confirmation of lymphoma or carcinoma re-
quiring treatment by surgery, chemotherapy,
hormonotherapy, radiotherapy, or targeted therapy with a cu-
rative intention as estimated by oncologists. The locations in-
cluded colon, rectum, anal canal, breast, oesophagus, ear,
nose and throat, kidney, prostate, bladder, lung, stomach, bil-
iary ducts, ovary, womb, endometrium, and pancreas (Table
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S1). Were also included hepatocellular carcinomas, all large
diffused B-cell lymphomas, all T peripheral lymphomas, and
all low-grade lymphomas: lymphocytic, lymphoplasmacytic,
follicular, mantle, marginal zone (mucosa-associated lymphoid
tissue and others), and primary unknown adenocarcinomas.
Exclusion criteria were Eastern Cooperative Oncology Group
test score>2, serious psychiatric or cognitive problems, no ba-
sic fluency in the French language, and functional disability
leading to a total inability to walk. Finally, patients participat-
ing in concurrent studies containing physical activity, those in
palliative care, and those under legal protection were also in-
eligible. The trial was approved by the institute and ethical
committees.
Recruitment and randomization
All potentially eligible patients were selected and included be-
fore starting treatment in the oncology department. If the pa-
tient agreed orally to participate, he or she was subsequently
randomized to the usual care group (UCG) or intervention
group (IG) and centralized via Internet. Randomization was
stratified on the centres and used allocation by random
blocks of four or six. Patients were equally randomized to
the UCG or the IG (Figure 1). The allocation sequence was
centralized via Internet and concealed from the project team.
Only the oncology team was aware of the group allocation of
each patient via Internet and was able to deliver the
CAPADOGE booklet to the patients in the IG at V1. Thus, no
double or simple blind was possible.
Usual care group
The UCG received without comments the ‘PNNS booklet’
(French National Nutrition Health Program), which provides
the current national recommendations for physical activity
for people of this age group, that is, half an hour a day of
any type of physical activity.
Intervention group
The physical activity intervention involved strength, balance,
proprioception, flexibility, and aerobic training.20 The aim of
the programme was to maintain fitness. Exercise sessions
were conducted twice a week at the beginning of the inter-
vention but more were proposed according to the patients’
motivation and capabilities. Strength training comprised up-
per and lower body exercises: arm-curl, squats, hip abduc-
tion, hip adduction, and more. First instruction was to
perform 10 repetitions of each exercise without load to en-
sure an appropriate adaptation to resistance exercise. There-
after, if they were well tolerated, loads were included, and
number of repetitions was increased for additional benefit.
The CAPADOGE booklet (which included images of different
strength, balance, proprioception, flexibility, and aerobic ex-
ercises) was used so that the patients, apart from the advice
they received over the phone, had a visual aid to be able to
correctly carry out the exercises. The intensities that were
proposed to the patients ranged from low to high and fo-
cused on avoiding pain and exhaustion. The instructor re-
ceived patients’ previous SPPB and International Physical
Activity Questionnaire (IPAQ) assessment results to know
their functional performance and habitual physical activity
level. Then, the choice of intensity was based on the patient’s
feedback at each phone call to reach the highest intensity
possible for each subject. Balance and proprioception training
included exercises difficulty progression starting in sitting po-
sition or standing with two arms support. Then patients were
invited to increase the complexity of movements according to
their feedback: with one hand and finally without hands sup-
port if possible. Sessions finished with stretching exercises.
In addition to the exercise sessions, aerobic training was
implemented through individualized recommendations re-
garding time and intensity to perform on their own. At first
phone call, the instructor asked the patients about their daily
physical activity (e.g. walking, shopping, and stair climbing).
The instructor took this information into account together
with the SPPB and IPAQ scores to encourage them to in-
crease their daily amount of physical activity.
Advice was given by the same professional instructor with
a degree in physical activity and sport sciences and trained in
providing adapted physical activity to older adults. Phone
calls were made twice a month during the first 6 months
and then monthly until 1 year. The instructor reported all
the exercises that the patients said that they had performed
from the last phone call, in order to review each exercise and
suggest individualized physical activity advice until the next
phone call.
Study design and measurements
Participants were assessed immediately before the cancer
treatment (visit 1, V1) and at 3 (V2), 6 (V3), 12 (V4), 18 (V5),
and 24 (V6) months. Assessments were performed in each
centre by clinical research assistants blind for group allocation.
Data were anonymized by use of an identification code. Out-
come measures were keyed in by data managers. The main
baseline assessment included body mass index, Mini-Mental
State Examination,21 nutritional status [Mini Nutritional As-
sessment (MNA)—Short Form],22 hand grip strength, SPPB,16
Eastern Cooperative Oncology Group performance status,
level of physical activity measured using the self-reported
IPAQ,23 Quality of Life Questionnaire (QLQ-C30),24 verbal flu-
ency,25 Cumulative Index Rating Scale–Geriatric,26 and C-
reactive protein dosage (mg/L). Frailty status was measured
with a slightly modified version of the Fried criteria12 (Table
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S2). We used a hand-held dynamometer (Micro-FET-2®) to as-
sess the grip strength criterion, the QLQ-C30 fatigue symptom
subscore24,27 for the self-reported exhaustion criterion, the
MNA22 weight loss item for the weight loss criterion, and the
IPAQ score for the decreased physical activity criterion.23
Outcomes
The primary outcome was the proportion of subjects with
a 1 year decreased SPPB16 score of 1 point or more as
compared with baseline. A 1-point change in total SPPB
score has been demonstrated to be of clinical relevance
and to represent a substantial meaningful change.28 It
was reported that 1-point change can identify changes in
the ability to walk one block, ability to climb one flight
of stairs, or any self-perceived change in mobility.28 The
SPPB includes tests of gait speed, standing balance, and
rising from a chair. For tests of standing balance, partici-
pants attempted to maintain the side-by-side, semi-
tandem, and tandem positions for 10 s. Usual pace during
a 4 m walk was timed from a standing start, and
Figure 1 Study flow diagram.
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participants were scored according to the time taken.
Lastly, the third SPPB test consists of the time to rise from
a chair as quickly as possible five times. Overall, the maxi-
mal SPPB score is 12 (4 points in each test). The secondary
outcomes included the proportion of subjects with a 2 year
decreased SPPB score of 1 point or more, self-reported
physical activity, cognitive assessments (verbal fluency),
and evolution during the 2 year follow-up, and the occur-
rence of clinical outcomes: hospitalization, institutionaliza-
tion, number of self-reported falls since the previous visit,
and mortality.
Statistical analyses
Considering the recruitment capacity of the study, a sample
size of 300 patients was required to provide 80% statistical
power and a two-sided type I error rate of 5% to detect a
minimal difference in the proportion of patients with a lower
SPPB, assuming less than 15% in the IG compared with 30% in
the UCG and a 10% loss of follow-up.
Analysis was performed on an intention-to-treat basis in a
conventional manner: the patients were allocated to their
randomization group whatever the intervention they actually
received in order to keep the benefits of the randomization.
For the main outcome, a missing = failure strategy was used:
missing data were replaced by failure value, that is, loss of 1
SPPB point, being in the least favourable situation for the in-
novative intervention. The maximal bias strategy completed
the sensitivity analysis.
Categorical variables such as 1 or 2 year 1 point SPPB
decrease and clinical outcomes were analysed with logistic
regression with adjustment for centre, gender, age
(>80 years or not), and chemotherapy (yes/no). Some
models for secondary outcomes could not be fully adjusted
owing to convergence issues (see footnotes in tables).
Continuous variables were described as mean, median,
standard deviation, minimum, maximum, and interquartile
range values when appropriate. Linear mixed models were
used to estimate between-group differences accounting
for repeated measurements during the 2 year follow-up,
with subject-specific random intercept. All analyses for
secondary criteria were done with available data.
Subgroup analyses were specified a priori by gender and
breast cancer.
A P-value less than 0.05 was considered statistically signif-
icant. The data were analysed with SAS® base 9.3 (SAS Insti-
tute, Cary, NC, USA). Compliance was assessed by dividing
the number of phone calls made by the number of planned
phone calls for people with a complete follow-up. Efficiency
of advice was measured by dividing the number of items of
physical activity advice declared as effectively performed by
the number of phone calls made.
Results
Study participants
From October 2011 to May 2014, we screened 452 partici-
pants. Of these, 301 were eligible, agreed to participate,
and were allocated to either the UCG or the IG (Figure 1).
The mean age was 76.7 years, and 60.0% were women (Table
1). Of 300 individuals analysed, 249 (83%) completed the
12 month follow-up. Attrition was higher than the projected
rate (17% at 1 year) used for sample size calculations. Drop-
out reasons are listed in Figure 1. Among the 300 participants
who began the study, 186 (62%) completed the 24 month as-
sessment (Figure 1). Breast was the most frequent tumour
site (Table 1). Chemotherapy was used alone or in association
in 91 (60.7%) subjects from the IG and 89 (59.3%) in the UCG
(Table 1).
Intervention adherence
The compliance and efficiency rates for the 12 month period
were as follows: 81.1% of the 18 planned phone calls were
actually made, and 70.1% of physical activity advice was de-
clared as effectively performed by participants with a com-
plete follow-up.
Functional outcomes
After 1 year, a decline of 1 point or more on the SPPB was ex-
perienced by 14.0% of participants in the UCG and 18.7% in
the IG (P = 0.772; Table 2). Robustness analysis with the max-
imal bias strategy was also performed, but given the propor-
tion of missing data, the results were hardly interpretable.
The odds ratio varied from 0.1 to 16.6 according to the orien-
tation of the bias. At 2 years, 18.0% of UCG participants and
9.3% of IG participants had declined on the SPPB (P = 0.057;
Table 2). Linear mixed models showed a similar evolution of
both the UCG and IG for SPPB, gait speed, IPAQ score, and
verbal fluency after 3, 6, 12, 18, and 24 months (NS; Tables
3 and S3).
In subgroup analyses, proportions of decline of 1 or more
points on the SPPB did not significantly differ after 1 year
when participants were categorized by breast cancer
(P = 0.119; Table 2) and gender (P = 0.068; Table 2). However,
after 2 years, 29.8% of UCG and 5.0% of IG breast cancer par-
ticipants (P = 0.006; Table 2) had declined on the SPPB. In
women, 21.7% of UCG and 6.2% of IG participants
(P = 0.019; Table 2) had declined on the SPPB. The differences
between both groups were not significant in men at 1
(P = 0.622; Table 2) and 2 years (P = 0.943; Table 2). We per-
formed additional analyses to explore the role of nutritional
status according to MNA categories. At the 2 year visit,
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among participants with a normal nutritional status, 24.5% of
UCG and 11.1% of IG participants (P = 0.009; Table 2) had de-
clined on the SPPB. There were no differences in SPPB decline
for other MNA categories.
Clinical outcomes
Incidence of falls (UCG: 7% and IG: 7%), hospitalization (UCG:
16% and IG: 18%), institutionalization (UCG: 4% and IG: 9%),
Table 1. Baseline characteristics of patients
Characteristics
Usual care group (n = 150) Intervention group (n = 150)
n % n %
Age (years)
Mean 76.6 76.8
SD 5.0 5.1
Female gender 83 55.3 97 64.7
Body mass index (kg/m2)
Mean 26.1 26.2
SD 4.6 4.4
MMSE, 0–30
Mean 26.8 26.8
SD 2.9 2.9
MNA questionnaire, 0–14
Good nutrition, score >11 49 33.8 54 38.6
At risk/poor nutrition, score ≤11 96 66.2 86 61.4
SPPB, 0–12
Mean 9.2 8.9
SD 2.3 2.6
ECOG performance status, n (%)
0 86 65.6 74 56.9
1 40 30.5 49 37.7
2 5 3.8 7 5.4
IPAQ, n (%)
<600 MET 29 20.1 26 19.1
600–2999 MET 52 36.1 47 34.6
≥3000 MET 63 43.8 63 46.3
Fatigue (QLQ-C30) (0–100)
Mean 30.5 26.6
SD 28.9 27.1
Physical activity (QLQ-C30) (0–100)
Mean 23.3 16.7
SD 23.1 19.0
Frailty status, n (%)
Not frail 90 74.4 83 72.8
Frail 31 25.6 31 27.2
Verbal fluency, 15 s
Mean 6.6 6.8
SD 2.3 2.2
Verbal fluency, 15–60 s
Mean 9.3 9.2
SD 6.6 4.1
Co-morbidity, CIRS-G
Normal, no grade 3–4 co-morbidities 115 76.7 121 80.7
1 co-morbidity grade 3–4 28 18.7 24 16.0
≥2 co-morbidities grade 3–4 7 4.7 5 3.3
C-reactive protein (mg/L)
Median 3 4
IQR 1–9 2–8
Cancer origin
Breast 47 31.3 60 40.0
Colon 20 13.3 15 10.0
Other 83 55.3 75 50.0
Treatment
Surgery 45 30.0 53 35.3
Chemotherapy 90 60.0 91 60.7
Radiation 58 38.7 59 39.3
Hormone therapy 32 21.3 29 19.3
Targeted therapy 2 1.3 3 2.0
CIRS-G, Cumulative Index Rating Scale–Geriatric; ECOG, Eastern Cooperative Oncology Group; IPAQ, International Physical Activity Ques-
tionnaire; IQR, interquartile range; MMSE, Mini-Mental State Examination; MNA-SF, Mini Nutritional Assessment—Short Form; QLQ-C30,
Quality of Life Questionnaire; SD, standard deviation; SPPB, short physical performance battery.
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and death (UCG: 11% and IG: 10%) did not differ significantly
between UCG and IG participants at 1 year. At 2 years, results
for falls (UCG: 11% and IG: 10%), hospitalization (UCG: 29%
and IG: 25%), institutionalization (UCG: 6% and IG: 9%),
and death (UCG: 20% and IG: 20%) were also similar in
both groups.
Discussion
The CAPADOGE study showed that both personalized phys-
ical activity advice given by phone and usual care based on
the current national recommendations led to a similar pro-
portion of patients whose SPPB score decreased by ≥1
point after 1 year. Due to the good prognosis with curative
intention treatment of the participants included, we
expected to recruit participants with a high SPPB score,
that is, little likelihood of improvement but a potential de-
cline. Indeed, this study confirmed our hypothesis of a high
proportion of subjects with a 1 year decrease of 1 or more
points on the SPPB. The proportion was around 15%
at 1 year as compared with 30% in a geriatric frail
population.29
In women with breast cancer, the intervention had effi-
ciently slowed the functional decline after 2 years. This
was not the case after 1 year possibly owing to their low
muscle mass, strength, and physical activity level during
and after chemotherapy treatment and their association
with functional decline.30–33 However, the significant results
at 2 years despite the fact that we had 62% participation,
and thus a lack of power, strongly suggest the positive ef-
fect of physical activity at 2 years. We added a subgroup
analysis to explore the role of nutritional status in the re-
sponse to advice on physical activity. At the 2 year visit,
only the subgroup of subjects with normal nutritional status
had benefited functionally from the intervention. Thus, a
multimodal intervention including nutrition, which has been
demonstrated to be feasible and safe, should be considered
in any future trials with cancer patients.34 Interestingly, par-
ticipants with breast cancer, women with any cancer and
normal nutritional status, showed lower refusal rates com-
pared with men and participants who had other types of
cancer (data not shown). Because of the attrition observed
at 24 months, this was still the case for participants still
followed at that time. Indeed, the effect observed in those
with breast cancer was strong enough to remain significant
after correction for test multiplicity (e.g. Bonferroni correc-
tion). However, the difference by gender in the effect of
the intervention may be because breast cancer concerns
only women and because the number of patients with
breast cancer was large. The low number of patients with
other cancer sites did not allow other subgroup analyses
to be performed.
Another study in younger participants and after comple-
tion of all surgery, chemotherapy, and/or radiation therapy
showed that phone-based physical activity advice was feasi-
ble and effective in improving functional capacity in breast
Table 2. Short physical performance battery change from baseline
n (%)
P*
12 months
P*
24 months
Usual care group Intervention group
12 months 24 months 12 months 24 months
Main outcome n = 72 n = 67 n = 74 n = 58
SPPB change vs. baseline
No change or improvement 51 (70.8) 40 (59.7) 46 (62.2) 44 (75.9)
Decline ≥1 point 21 (29.2) 27 (40.3) 28 (37.8) 14 (24.1) 0.772a 0.057b
Breast cancer subgroup n = 27 n = 31 n = 31 n = 28
SPPB change vs. baseline
No change or improvement 20 (74.1) 17 (54.8) 18 (58.1) 25 (89.3)
Decline ≥1 point 7 (25.9) 14 (45.2) 13 (41.9) 3 (10.7) 0.119b 0.006b
Male subgroup n = 33 n = 23 n = 28 n = 21
SPPB change vs. baseline
No change or improvement 22 (66.7) 14 (60.9) 20 (71.4) 13 (61.9)
Decline ≥1 point 11 (33.3) 9 (39.1) 8 (28.6) 8 (38.1) 0.622b 0.943b
Female subgroup n = 39 n = 44 n = 46 n = 37
SPPB change vs. baseline
No change or improvement 29 (74.4) 26 (59.1) 26 (56.5) 31 (83.8)
Decline ≥1 point 10 (25.6) 18 (40.9) 20 (43.5) 6 (16.2) 0.068b 0.019b
Normal nutritional status subgroup n = 25 n = 24 n = 34 n = 31
SPPB change vs. baseline
No change or improvement 17 (68.0) 12 (50.0) 22 (64.7) 25 (80.6)
Decline ≥1 point 8 (32.0) 12 (50.0) 12 (35.3) 6 (19.4) — 0.009a
P*, P for overall groupwise difference; SPPB, short physical performance battery.
aAdjusted for centre, gender, age, and treatment.
bAdjusted for centre, age, and treatment.
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cancer survivors,35 which was the most frequent cancer
among women included. Thus, phone-based physical activ-
ity interventions might be efficient in improving objectively
measured physical functioning among older adults with can-
cer. As stated earlier, the phone-based physical activity in-
tervention was carried out to obtain greater outreach to
patients, because our hypothesis was that those with lower
physical function would not take part in a supervised exer-
cise programme. However, in the present study, even
though the compliance and the efficiency rates of the pro-
gramme were high, the intensity of the exercises may have
been too low, so the advice was not sufficient to prevent
functional decline after 1 year. Therefore, due to the low
effect of this intervention at 1 year, adding a digital virtual
supervised session could be a key factor in getting patients
to understand that the training programme is complemen-
tary to medical treatment. In addition, being part of the
current study may have increased awareness in the UCG
of the health benefits associated with physical activity and
may have resulted in maintaining physical function during
the programme. It is also possible that the effects of cancer
treatment were still strong enough at 1 year to block the
benefits of physical activity in older adults with cancer.
The anti-anabolic consequences of cancer cachexia may ex-
plain this lack of effect at 1 year. MNA is currently used as
a marker of cancer cachexia and has a strong prognostic
value, mainly for appetite and sarcopenia.36 A correlation
between the biochemical markers of cachexia and MNA
score has been shown in older patients with cancer.37 In
addition, although exercise could be an attractive therapy
for cancer cachexia, there is still a lack of studies focusing
on the efficacy of exercise programmes in older cancer
population with regard to functional issues.38
These findings are consistent with previous reports that
did not find any self-reported functional benefits at 1 year.4
However, other studies showed slowing down of self-
reported functional decline after older adults undergoing
and recovering from cancer treatment had received physical
activity advice, even though the IG still showed functional
decline.17 Thus, the phone-based physical activity interven-
tion seems to be a suitable solution to prevent or delay phys-
ical performance decline in older adults with cancer. Our
hypothesis should have concerned functional status 2 years
after the start of the treatment rather than after the first
year, because the effects of the treatments that patients
have undergone still seemed to be strong enough to mask
the beneficial effects of physical activity. However, in the
CAPADOGE trial, the assessment schedule was adapted to
cancer treatment follow-up visits to minimize loss to follow-
up, and we expected high attrition rates in the second year.
Even the number of participants who dropped out was
slightly higher in the IG, so the number of patients lost to
follow-up in both groups is a major limitation of the study.
Caution is also required in generalizing our results to patientsTa
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whose cancer carries a poor prognosis, to the cognitively im-
paired, and to frail older adults. In addition, type of cancer,
prognosis, and treatment may have influenced participation
in the physical activity programme, and together with the
high death rate of the study, participants may have con-
founded our analysis. However, the good prognosis as subjec-
tively assessed by oncologists of all participants included and
the adequate randomization in the two groups depending on
the type of cancer (Table S1) suggest that the aforemen-
tioned factors may not have influenced participation in the
physical activity programme and thus the outcomes. We
planned our subgroup analysis according to cancer type, but
due to the small number in each cancer subgroup, only those
with breast cancer were analysed separately. Indeed, the rate
of cachexia may have been different according to cancer
type. The subgroup analysis according to the MNA was per-
formed to explore this possibility. Another limitation is that
the secondary outcome measure of physical activity together
with the measure of compliance with the exercise prescrip-
tion was not objectively assessed via accelerometers. This
point gives less weight and credibility to the physical activity
level assessed in this study in comparison with other studies
in which accelerometers were used.39 Responses may have
reflected wishful thinking more than the actual level of phys-
ical activity. For these reasons, our physical activity data may
be inaccurate. However, acceptance of using an accelerome-
ter for such a long duration would probably have been low.
The number of clinical trials using objective monitors in can-
cer patients and survivors is increasing,40 but accelerometers
are normally used only for a few days and not in the long
term. Thus, the lack of effect of intervention at 1 year may
have been due to a lack of effect to achieve a sufficient level
of physical activity, as advocated over the phone.
The study also has strengths. First, the physical activity in-
tervention was simple to implement, low-cost, practical, and
broadly applicable to older patients treated for cancer. Sec-
ond, the findings provide preliminary evidence that physical
activity may prevent long-term functional loss in older adults
with breast cancer. Third, although poor physical function is
known to be a strong predictor of adverse outcomes like dis-
ability, hospitalization, and mortality,16 this is the first long-
term study with a large sample to focus on objectively mea-
sured functional decline among older patients treated for
cancer, instead of measuring it subjectively.41 Fourth, compli-
ance was similar to that in other studies focusing on interven-
tions in older participants with cancer.42
As in other research investigating physical activity in older
participants, hospitalization rate and death were similar in
both groups.43 However, given the small number of hospitali-
zations, these data are inconclusive, so further studies are
needed to assess the effects of physical activity advice on hos-
pitalization rates in older patients with cancer. To date, the
CAPADOGE study is the largest and longest randomized trial
assessing the effects of physical activity advice that focused
on objectively measured functional decline in older patients
treated for cancer. Future studies should focus on digital
virtual supervised training in order to design a highly efficient
programme for the recovery of older patients treated for
cancer and designed for a main outcome measured at 2 years.
Conclusions
Compared with usual care given according to the current na-
tional recommendations in France, personalized advice on
physical activity given over the phone did not reduce func-
tional decline at 1 year although significant differences were
observed after 2 years in women and in the breast cancer
subgroup. Thus, these results highlight the potential for pro-
viding efficient personalized physical activity advice over the
phone in older adults with cancer. Future work should focus
on comparing the effects of digital virtual supervised training
and its combination with the currently recommended usual
care in older adults with cancer.
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